Stock listing
Blossomhill Therapeutics, Inc.
Selected listing: BLSM · NASDAQ · USD · US
Blossomhill Therapeutics, Inc. (NASDAQ:BLSM), Health Technology. Latest release Sep 18, 2026: BlossomHill Therapeutics Reports Second Quarter 2026 Financial…
- Ticker
- NASDAQ:BLSM
- Asset type
- Stock
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- Exchange
- NASDAQ
- Currency
- USD
About Blossomhill Therapeutics, Inc.
Blossomhill Therapeutics, Inc. (BLSM) is listed on 6ix with investor news, events, company updates, and market data in one place. Follow the company page to track new releases, upcoming presentations, and the latest information available on 6ix.
Latest news from Blossomhill Therapeutics, Inc.
BlossomHill Therapeutics Reports Second Quarter 2026 Financial Results
September 18, 2026
BlossomHill Therapeutics to Present at the 8th Annual RAS-Targeted Drug Development Summit & H.C. Wainwright 28th Annual Global Investment Conference
September 3, 2026
BlossomHill Therapeutics to Present Updated Data from Ongoing Phase 1/2 SOLARA Trial of its Macrocyclic OMNI-EGFR™ Inhibitor, BH-30643, in EGFR-mutant NSCLC at the 2026 World Conference on Lung Cancer
September 1, 2026
BlossomHill Therapeutics Announces FDA Fast Track Designation for BH-30643, a Macrocyclic OMNI-EGFR Inhibitor for the Treatment of Advanced EGFR C797S-positive NSCLC
August 19, 2026
BlossomHill Therapeutics Announces FDA Fast Track Designation for BH-30643, a Macrocyclic OMNI-EGFR™ Inhibitor for the Treatment of Advanced EGFR C797S-positive NSCLC
August 18, 2026
Research Blossomhill Therapeutics, Inc.
Blossomhill Therapeutics, Inc. company profile
View the public company page for Blossomhill Therapeutics, Inc. on 6ix.
Blossomhill Therapeutics, Inc. news
Read company news and market updates connected to Blossomhill Therapeutics, Inc..
Blossomhill Therapeutics, Inc. investor events
Find investor webinars, events, and replay context for Blossomhill Therapeutics, Inc..